The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The invention relates to a method of preparing an [18F] radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on both the yield and the purity of the product of the radio-labelling process.
Provided is a method of preparing an aqueous ascorbic acid solution having a pH of 2.0 to 4.0, the method comprising: providing an initial aqueous solution of ascorbic acid and a base, wherein the initial solution has a pH of 5.0 to 8.0; and combining the initial solution with a second acid to obtain an ascorbic acid solution having a pH of 2.0 to 4.0. Also provided is the use of an aqueous ascorbic acid solution having a pH of 2.0 to 4.0 prepared by a described method as a radiostabiliser of a radio-labelled compound.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present invention concerns a HPLC separation method useful in the synthesis of [18F]-labelled compounds, including positron emission tomography (PET) tracers. The method of the invention addresses constraints of previous methods imposed by the needs of free 5 [18F]fluoride. The present invention provides a simplified process that enables rapid separation and analysis of free [18F]fluoride and chemical impurities in the synthesis of [18F]-labelled compounds.
The present invention relates to improved radiopharmaceutical compositions in sealed containers, where the container closure has an ETFE (ethylene-tetrafluoroethylene copolymer) coating. Also disclosed are kits for radiopharmaceutical preparation using the sealed containers, as well as methods of preparation of radiopharmaceuticals using the sealed containers.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
6.
APPARATUS, METHODS, AND MODELS FOR THERAPEUTIC PREDICTION
Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. An example apparatus includes a plurality of models to predict at least one of a) a toxicity in response to immunotherapy or b) an efficacy of the immunotherapy, the plurality of models trained and validated using data from previous patients; and processor circuitry. The processor circuitry is to execute the instructions to: accept an input, via an interface, of data associated with a first patient; generate, using at least one of the plurality of models, a prediction of at least one of: a) a toxicity occurring during immunotherapy according to a treatment plan for the first patient or b) an efficacy of the immunotherapy treatment plan for the first patient; and output a recommendation for the first patient with respect to the treatment plan.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
7.
MODEL GENERATION APPARATUS FOR THERAPEUTIC PREDICTION AND ASSOCIATED METHODS AND MODELS
Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. An example apparatus includes processing circuitry to at least: process input data pulled from a record to form a set of candidate features; train a first model and a second model using the set of candidate features; test the first model and the second model to compare performance of the first model and the second model; select at least one of the first model or the second model based on the comparison; store the selected first model and/or second model; and deploy the selected first model and/or second model to predict a likelihood of at least one of: a) a toxicity occurring due to immunotherapy according to a treatment plan or b) efficacy of the treatment plan for a patient.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
8.
MODEL GENERATION APPARATUS FOR THERAPEUTIC PREDICTION AND ASSOCIATED METHODS AND MODELS
Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. A balance of precision and recall can be applied to at least one of a toxicity-related model or an efficacy-related model to configure immunotherapy treatment of a patient and/or cohort of patients. Model output can be evaluated differently depending on a determine patient selection criterion to trigger different actions.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
The present invention provides a novel method for the preparation of 18F-fluoride (18F) for use in radiofluorination reactions. The method of the invention finds use especially in the preparation of 18F-labelled positron emission tomography (PET) tracers. The method of the invention is particularly advantageous where bulk solutions are prepared and stored in prefilled vials rather than being freshly prepared on the day of synthesis. Also provided by the present invention is a radiofluorination reaction which comprises the method of the invention, as well as a cassette for use in carrying out the method of the invention and/or the radiofluorination method of the invention on an automated radiosynthesis apparatus.
C07C 51/363 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogenPreparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by substitution of halogen atoms by other halogen atoms
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises:
(i) a flowpath comprising a first end and a second end; and
(ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise:
(a) 1-5 composition vials;
(b) 1-3 SPE cartridges;
(c) 4-10 solvent vials;
(d) a water vial; and
(e) a transfer line.
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises:
(i) a flowpath comprising a first end and a second end; and
(ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise:
(a) 1-5 composition vials;
(b) 1-3 SPE cartridges;
(c) 4-10 solvent vials;
(d) a water vial; and
(e) a transfer line.
The present invention also provides a method for determining optimised SPE purification conditions for a compound from a composition, the method comprising:
(i) provision of a cassette as defined in any of claims 1 to 7;
(ii) the cassette comprising a composition of the compound in said composition vial(s) or addition of such a composition to said crude reaction vial(s);
(iii) passing an aliquot of said composition into each of said 1-3 SPE cartridges;
(iv) passing a particular combination of aliquots of solvent from at least 4 of said 4-10 solvent vials into one or more of the SPE cartridges, wherein the solvent in each of said 4-10 solvent vials is either a different solvent or the same solvent at different concentration;
(v) eluting the compound to be purified from the or each SPE cartridge;
(vi) evaluating the eluted products of step (v); and
(vii) determining the optimised purification conditions by comparing the eluted products of step (v) from each cartridge and each solvent.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin.
The present invention also provides a radiopharmaceutical composition comprising: (i) a radio-labelled compound; (ii) a stabilizer of the radio-labelled compound, wherein the stabilizer comprises: ascorbic acid, aspartic acid, cysteine, maleic acid, gentisic acid, glutathione, glutamic acid, mannitol, nicotinamide, calcium chloride, N-t-butyl-alpha-phenylnitrone (PBN), tartaric acid, para-aminobenzoic acid (pABA), chloride ions or salts or combinations thereof; and (iii) a cyclodextrin.
The invention relates to a method of preparing an [18F]radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on both the yield and the purity of the product of the radio-labelling process.
Provided is a method of preparing an aqueous ascorbic acid solution having a pH of 2.0 to 4.0, the method comprising: providing an initial aqueous solution of ascorbic acid and a base, wherein the initial solution has a pH of 5.0 to 8.0; and combining the initial solution with a second acid to obtain an ascorbic acid solution having a pH of 2.0 to 4.0. Also provided is the use of an aqueous ascorbic acid solution having a pH of 2.0 to 4.0 prepared by a described method as a radiostabiliser of a radio-labelled compound.
The invention relates to a method of preparing an [18F]radio-labelled compound, wherein the water content is controlled. Controlling the water content and the origin of the water within the reaction process has a significant effect on both the yield and the purity of the product of the radio-labelling process.
Provided is a method of preparing a vial containing an ascorbic acid solution, the method comprising: providing an aqueous solution of ascorbic acid and a base, wherein the solution has a pH of 5.0 to 8.0; degassing the solution with an inert gas; dispensing the solution into a vial; degassing the vial headspace with an inert gas; and sealing the vial. Also provided is a vial containing: an aqueous solution of ascorbic acid and a base, wherein the solution has a pH of 5.0 to 8.0; and an inert gas.
The present invention concerns a HPLC separation method useful in the synthesis of [18F]-labelled compounds, including positron emission tomography (PET) tracers. The method of the invention addresses constraints of previous methods imposed by the needs of free 5 [18F]fluoride. The present invention provides a simplified process that enables rapid separation and analysis of free [18F]fluoride and chemical impurities in the synthesis of [18F]-labelled compounds.
The present invention concerns a HPLC separation method useful in the synthesis of [18F]-labelled compounds, including positron emission tomography (PET) tracers. The method of the invention addresses constraints of previous methods imposed by the needs of free 5 [18F]fluoride. The present invention provides a simplified process that enables rapid separation and analysis of free [18F]fluoride and chemical impurities in the synthesis of [18F]-labelled compounds.
A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to radiotracer compositions which comprises 18F-labelled c-Met binding peptides. The invention provides said compositions, as well as associated automated methods of preparation and cassettes.
A method of labelling biological molecules with 18F, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (H-bonding) into the metal complex scaffold, and how this can be utilized to improve the kinetics of fluoride incorporation. Also provided are pharmaceutical compositions, kits and methods of in vivo imaging.
C07F 5/00 - Compounds containing elements of Groups 3 or 13 of the Periodic Table
C07D 255/02 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups not condensed with other rings
The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of purifying a radiotracer which comprises 18F-labelled aminoxy-functionalised biological targeting moiety. The invention provides radioprotectant-containing radiopharmaceutical compositions of the tracers, as well as associated automated methods and cassettes.
A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/22 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the construction of the column
B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises: (i) a flowpath comprising a first end and a second end; and (ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise: (a) 1-5 composition vials; (b) 1-3 SPE cartridges; (c) 4-10 solvent vials; (d) a water vial; and (e) a transfer line. The present invention also provides a method for determining optimised SPE purification conditions for a compound from a composition, the method comprising: (i) provision of a cassette as defined in any of claims 1 to 7; (ii) the cassette comprising a composition of the compound in said composition vial(s) or addition of such a composition to said crude reaction vial(s); (iii) passing an aliquot of said composition into each of said 1-3 SPE cartridges; (iv) passing a particular combination of aliquots of solvent from at least 4 of said 4-10 solvent vials into one or more of the SPE cartridges, wherein the solvent in each of said 4-10 solvent vials is either a different solvent or the same solvent at different concentration; (v) eluting the compound to be purified from the or each SPE cartridge; (vi) evaluating the eluted products of step (v); and (vii) determining the optimised purification conditions by comparing the eluted products of step (v) from each cartridge and each solvent.
The present invention provides a cassette for determining optimised solid phase extraction (SPE) purification conditions, wherein said cassette comprises: (i) a flowpath comprising a first end and a second end; and (ii) a plurality of valves oriented along said flowpath, wherein each of said plurality of valves is selectively fluidly connected to one of a number of components, wherein said components comprise: (a) 1-5 composition vials; (b) 1-3 SPE cartridges; (c) 4-10 solvent vials; (d) a water vial; and (e) a transfer line. The present invention also provides a method for determining optimised SPE purification conditions for a compound from a composition, the method comprising: (i) provision of a cassette as defined in any of claims 1 to 7; (ii) the cassette comprising a composition of the compound in said composition vial(s) or addition of such a composition to said crude reaction vial(s); (iii) passing an aliquot of said composition into each of said 1-3 SPE cartridges; (iv) passing a particular combination of aliquots of solvent from at least 4 of said 4-10 solvent vials into one or more of the SPE cartridges, wherein the solvent in each of said 4-10 solvent vials is either a different solvent or the same solvent at different concentration; (v) eluting the compound to be purified from the or each SPE cartridge; (vi) evaluating the eluted products of step (v); and (vii) determining the optimised purification conditions by comparing the eluted products of step (v) from each cartridge and each solvent.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin. The present invention also provides a radiopharmaceutical composition comprising: (i) a radio-labelled compound; (ii) a stabilizer of the radio-labelled compound, wherein the stabilizer comprises: ascorbic acid, aspartic acid, cysteine, maleic acid, gentisic acid, glutathione, glutamic acid, mannitol, nicotinamide, calcium chloride, N-t-butyl-alpha-phenylnitrone (PBN), tartaric acid, para-aminobenzoic acid (pABA), chloride ions or salts or combinations thereof; and (iii) a cyclodextrin.
The present invention provides a radiopharmaceutical composition comprising the following four components: (i) a radio-labelled compound; (ii) ethanol; (iii) a stabilizer of the radio-labelled compound; and (iv) a cyclodextrin. The present invention also provides a radiopharmaceutical composition comprising: (i) a radio-labelled compound; (ii) a stabilizer of the radio-labelled compound, wherein the stabilizer comprises: ascorbic acid, aspartic acid, cysteine, maleic acid, gentisic acid, glutathione, glutamic acid, mannitol, nicotinamide, calcium chloride, N-t-butyl-alpha-phenylnitrone (PBN), tartaric acid, para-aminobenzoic acid (pABA), chloride ions or salts or combinations thereof; and (iii) a cyclodextrin.
18F-fluoride (18F) for use in radiofluorination reactions. The method of the invention finds use especially in the preparation of 18F-labelled positron emission tomography (PET) tracers. The method of the invention is particularly advantageous where bulk solutions are prepared and stored in prefilled vials rather than being freshly prepared on the day of synthesis. Also provided by the present invention is a radiofluorination reaction which comprises the method of the invention, as well as a cassette for use in carrying out the method of the invention and/or the radiofluorination method of the invention on an automated radiosynthesis apparatus.
18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The present approach relates to determining a reference value based on image data that includes a non-occluded vascular region (such as the ascending aorta in a cardiovascular context). This reference value is compared on a pixel-by pixel basis with the CT values observed in the other vasculature regions. With this in mind, and in a cardiovascular context, the determined FFR value for each pixel is the ratio of CT value in the vascular region of interest to the reference CT value.
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).
The present invention relates a method of monitoring an automated radiosynthesizer during a run and the radiosynthesizer having a number of individual activity detectors operably associated therewith. The method comprises the steps of recording S10 activity data from each activity detector; accessing S20 historic data from a data storage; detecting S30 precursor of yield drop in the recorded activity data based on the historic data; predicting (S40 yield when synthesizing a tracer with the radiosynthesizer based on the detected precursor of yield drop; and initiating S50 actions related to a level of predicted yield.
A medical system useful in the determination of future disease progression in a subject. More specifically the present invention applies machine learning techniques to aid prediction of disease pathology and clinical outcomes in subjects presenting with symptoms of cognitive decline and to expedite clinical development of novel therapeutics.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Radiopharmaceuticals; markers for diagnostic use;
pharmaceutical and veterinary products; pharmaceutical
preparations for human and veterinary use; biological
preparations for medical use; diagnostic products for
medical use; chemical preparations for medical use; food
supplements and nutritional supplements for medical use;
dietetic food and substances for medical and pharmaceutical
use; homeopathic and plant therapy compositions; sanitary
products for medical purposes; medicinal baths; dietetic
beverages for medical use; chemical reagents for medical
use, namely biomarkers; products for personal hygiene for
medical purposes; plasters, materials for dressings;
surgical and medical dressings. Medical devices for diagnostic use for administering
contrast media; medical diagnostic instruments; testing
instruments for use in medical diagnosis; diagnostic
apparatus for medical use; medical and veterinary apparatus
and instruments; surgical apparatus and instruments;
instruments for collection of human body fluids; kits
containing medical instruments; containers for medical
samples; tubes for surgical applications; container
holders for samples; tubes for medical applications;
syringes for medical use; syringe needles for medical use;
containers especially adapted for depositing syringes. Training services in the following fields: health,
pharmaceutical and medical research, pharmaceutical and
medical development; publication of books and texts other
than advertising texts in the pharmaceutical, medical and
health fields; arranging and conducting of colloquiums,
conferences, congresses, seminars in the pharmaceutical,
medical and health fields; education in the pharmaceutical,
medical and health fields. Development of pharmaceutical products; pharmaceutical
research and development; testing on pharmaceutical
products; carrying out clinical trials for pharmaceutical
products; scientific research regarding medicine;
bio-informatic, chemical and biological analysis; research
in chemistry, cosmetology, biology, bacteriology, nutrition,
biotechnology; biological and bio-informatic research
services in the field of chemical, biological and
pharmaceutical products; software design and development in
the field of pharmaceutical, health and medical research;
Providing medical and scientific research information in the
field of pharmaceutical products and clinical trials;
research on chemical reagents for medical use, namely
biomarkers; design of databases in the field of
pharmaceutical research and development, medicine, genetics
and clinical trials. Pharmaceutical services; pharmacy advice; information and
advisory services relating to pharmaceutical products;
medical services; medical information services; providing
medical information; information services on the treatment
of diseases via an awareness program; providing information
with respect to pharmaceuticals.
A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 51/00 - Preparations containing radioactive substances for use in therapy or testing in vivo
43.
Methods of spatial normalization of positron emission tomography images
An adaptive template image for registering a PET or a SPECT image includes a template image model including variability of values for each voxel in a template image according to one or more control parameters.
An image quality control system is disclosed. The example system includes an artificial intelligence modeler to process image data and metadata from patient data to generate first feature(s)from the image data and to parse the metadata to identify study information. The example system includes a computer vision processor to identify second feature(s)in the image data. The example system includes a results evaluator to compare the first feature(s)and second feature(s)to generate a comparison and to evaluate the comparison,first feature(s), and second feature(s)with respect to the study information to generate an evaluation. The example system includes a quality controller to compare the evaluation to quality criterion(-ia)to produce an approval or rejection of the patient data, the approval to trigger release of the patient data and the rejection to deny release of the patient data.
An image quality control system is disclosed. The example system includes an artificial intelligence modeler to process image data and metadata from patient data to generate first feature(s) from the image data and to parse the metadata to identify study information. The example system includes a computer vision processor to identify second feature(s) in the image data. The example system includes a results evaluator to compare the first feature(s) and second feature(s) to generate a comparison and to evaluate the comparison, first feature(s), and second feature(s) with respect to the study information to generate an evaluation. The example system includes a quality controller to compare the evaluation to quality criterion(-ia) to produce an approval or rejection of the patient data, the approval to trigger release of the patient data and the rejection to deny release of the patient data.
G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
A flexible bag (1; 101; 201) comprising a component (3; 103; 203) inside the bag, wherein said flexible bag comprises a receiving device (5; 105; 205) provided in a wall (7; 107; 207) of the flexible bag, wherein said component (3; 103; 203) and said receiving device (5; 105; 205) are configured for being connectable to each other for keeping the component substantially stationary within the flexible bag when so connected.
Disclosed is an in-process cell monitoring device comprising: a flow channel having at least one inlet and at least one outlet exposeable to a cell culture; a microscope positionable to view the contents of a region of the channel; and a computer operable at least to count any cells in the region, providing a closed fluid circuit for cell monitoring. Disclosed also is a bioreactor including a cell culture volume, and an in-process cell monitoring device, said device comprising: a flow channel having at least one inlet and at least one outlet each in fluid communication with the volume, of sufficient cross-sectional area to allow fluids to drain from the inlet to the outlet; and a microscope positionable to view the contents of a region of the channel, and also A method for monitoring a cell culture including determining cell density.
A bioreactor vessel incudes a first compartment configured to receive a suspension comprising cells and a cell culture medium, for use in a cell processing operation, a second compartment for receiving an overflow of the cell culture medium from the first compartment, and an overflow separating the first compartment from the second compartment, the overflow being configured to maintain a level of the cell culture medium in the first compartment.
A cellbag bioreactor includes a stacked filter providing multiple porous membranes to define a filter cavity. Additionally, a filter within the cellbag bioreactor may be tethered so as to help maintain each membrane of a filter wetted during bioreactor operations.
A bioreactor vessel includes a body having upper and lower ends and a hollow interior cavity formed in the body, the interior cavity located between the upper and lower ends, the interior cavity being configured to receive biomaterials for processing. The interior cavity includes a lower boundary that is angled toward the lower end of the body such that the vessel may be tilted to allow biomaterials within the interior cavity to be extracted and concentrated and/or washed without the need for a separate bioprocessing device.
Systems and methods for tracking and management of a distributed ledger including information for a batch of radiopharmaceutical material are disclosed. Certain examples provide a computer-implemented method of managing radiopharmaceutical material including tracking, using at least one processor, a status of a batch of radiopharmaceutical material, the status to include a type, a quantity, and a timestamp associated with the batch of radiopharmaceutical material;generating a record in a first copy of a distributed ledger using the type, quantity, and timestamp associated with the batch of radiopharmaceutical material;updating the record based on at least one of usage of the batch of radiopharmaceutical material, resale of at least a portion of the batch of radiopharmaceutical material, and decay of the batch of radiopharmaceutical material; and sharing the record with a second copy of the distributed ledger.
Apparatus, non-transitory computer-readable storage medium, and computer-implemented method for distributed ledger management of nuclear medicine products
Systems and methods for tracking and management of a distributed ledger including information for a batch of radiopharmaceutical material are disclosed. Certain examples provide a computer-implemented method of managing radiopharmaceutical material including tracking, using at least one processor, a status of a batch of radiopharmaceutical material, the status to include a type, a quantity, and a timestamp associated with the batch of radiopharmaceutical material; generating a record in a first copy of a distributed ledger using the type, quantity, and timestamp associated with the batch of radiopharmaceutical material; updating the record based on at least one of usage of the batch of radiopharmaceutical material, resale of at least a portion of the batch of radiopharmaceutical material, and decay of the batch of radiopharmaceutical material; and sharing the record with a second copy of the distributed ledger.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G06Q 30/06 - Buying, selling or leasing transactions
Disclosed is a method for the production of a porous polymer membrane suitable for liquid filtration or analyte capture, comprising the steps of: providing a flowable composition (100) on a substrate (220) the composition including at least: photo-activatable monomer molecules, photo activation initiator molecules and photo- activation quencher molecules; providing one or more pulses (L) of laser light at at least one focal point in the composition of sufficient energy to locally polymerise the composition; moving the or each focal point relative to the previously polymerised composition in a continuous or stepwise predetermined manner to a multiplicity of further positions;and repeating the pulse(s) at those further positions such that a three dimensional matrix of the composition is polymerised leaving unpolymerized areas of a size equivalent to conventional polymer membrane pores.
Apparatus, systems, and methods for tracking and management of bioprocess and/or other sterile product inventory are disclosed. An example apparatus includes: a communication interface to receive a message from a radiofrequency identification circuit associated with a product via an antenna at a location; a keycode verifier to verify a keycode from the message as authentic and associated with the product; a certificate generator to provide, when the keycode is verified, a certificate for the product, the certificate to be sent from a cloud-based server to a local computing device at the location to enable use of the product; an inventory predictor to predict, based on an identification of the product and usage information for the product and/or the location, an exhaustion of the product at the location; an output generator to trigger an order of the product when the exhaustion of the product at the location is predicted.
The present invention provides a process to enhance the productivity such as yield of radioactive fluorine labeled flutemetamol.
in which the above step (a) is carried out at an internal temperature of reaction solution of 140° C. or higher.
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present invention relates to a method for conditioning reversed phase SPE cartridges that provides certain advantages compared with known such methods. The method of the invention finds particular use in the automated synthesis of radiolabeled compounds where SPE is used for example in the purification steps.
B01D 15/20 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
B01D 15/32 - Bonded phase chromatography, e.g. with normal bonded phase, reversed phase or hydrophobic interaction
C07B 59/00 - Introduction of isotopes of elements into organic compounds
The present invention provides a system for evaporating a radioactive fluid, a method for the synthesis of a radiolabelled compound including this system, and a cassette for the synthesis of a radiolabelled compound comprising this system. The present invention provides advantages over known methods for evaporation of a radioactive fluid as it reduces drastically the amount of radioactive gaseous chemicals that are released in the hot cell. It is gentler and more secure compared to the known process and provides access to radiosyntheic processes that may not been acceptable for safety reasons related to release of volatile radioactive gases during evaporation. In addition, the process yields are higher because the radioactive volatiles are labelled intermediate species.
C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
Disclosed is a product and method for sampling cells from a bioreactor, for the purposes of determining the cell count or to remove a sample and retain sterility of the sample for quality control (QC) assessment during a cell expansion in a bioreactor using vacuum tubes in combination with a sampling manifold (1) comprising:a primary fluid conduit (2);a connection port (3) positioned at one end of said fluid conduit (2) comprising means (4) for selective fluid connection of the interior of said fluid conduit (2) to the interior of a sampling reservoir (5); and a plurality of sampling ports (6a-e) disposed along said fluid conduit (2); wherein each of said plurality of sampling ports(6a-e) comprises means (7a-e) for selective fluid connection with an outlet (8a-e) adapted to connect to means (9) to permit exclusively unidirectional fluid flow from said primary fluid conduit.
A system comprising that includes a flow tube configured to provide a flow path through the flow tube. The system also includes a plurality of actuators distributed radially about the flow tube, wherein a first actuator of the plurality of actuators is configured to drive a first oscillation in a first plane and a second actuator of the plurality of actuators is configured to drive a second oscillation in a second plane. Further, the system includes a plurality of sensor sets disposed on the flow tube, wherein each sensor set comprises two or more sensors configured to sense the first oscillation, the second oscillation, or both.
The present application provides a means for differential diagnosis of Parkinson's disease and the clinically similar Parkinsonian disorders multiple system atrophy with predominantly Parkinsonian features (MSA-P) and progressive supranuclear palsy (PSP).
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The present invention relates to a method for collecting a biological sample, such as a forensic sample, the method comprising the steps of a) providing a swab including a handle wherein one tip or end of the handle is coated with fibres, such as polyester fibres, to form an absorbent flocked head, wherein the head having a surface area of 3-80 mm2 and wherein the swab head fits into a 10-200 µl volume reaction well/tube; b) collecting a biological sample comprising nucleic acid on the head by contact between the head and the sample, c) subjecting the nucleic acid in the sample to nucleic acid (NA)amplification. The invention also relates to a collection swab for use is said method.
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is amenable to automation. In particular, the method of the present invention comprises a method of purification carried out by means of solid phase extraction (SPE) alone.
The present invention relates a method of monitoring an automated radiosynthesizer during a run and the radiosynthesizer having a number of individual activity detectors operably associated therewith. The method comprises the steps of recording S10 activity data from each activity detector; accessing S20 historic data from a data storage; detecting S30 precursor of yield drop in the recorded activity data based on the historic data; predicting (S40 yield when synthesizing a tracer with the radiosynthesizer based on the detected precursor of yield drop; and initiating S50 actions related to a level of predicted yield.
The present invention relates a method of monitoring an automated radiosynthesizer during a run and the radiosynthesizer having a number of individual activity detectors operably associated therewith. The method comprises the steps of recording S10 activity data from each activity detector; accessing S20 historic data from a data storage; detecting S30 precursor of yield drop in the recorded activity data based on the historic data; predicting (S40 yield when synthesizing a tracer with the radiosynthesizer based on the detected precursor of yield drop; and initiating S50 actions related to a level of predicted yield.
The present invention provides a method for the synthesis of an injectable composition comprising a [18F]-labelled pyridaben derivative that is advantageous over prior methods. In particular, the method of the present invention comprises a method of radiosynthesis that permits a more facile purification using solid phase extraction (SPE).
Disclosed is a microscope stage translation mechanism (100) comprising: a drive (110) rigidly attached or attachable to a bed (105) which drive provides substantially linear motion of a drive element (114); a rocker (130) arranged for pivoting motion about pivot axis (A-A), said axis being stationary relative to said bed (105), the rocker having a first region (122) arranged to be directly engageable with the drive element (114), and a second region (124) distant, relative to the axis, from the first region (122); and a follower having a follower surface (134) arranged to be directly engageable with the second region (124) of the rocker, the follower (130) being attached or attachable to a vertically moveable part of the stage;the mechanism (100) being characterised in that the drive element (114) and the first region (122) have point contact at a first contact point (P) when engaged, and in that the second region (124) and the follower surface (134) also have point contact at a second contact point (P) when engaged.
A bioprocessing system includes a first module configured for enriching and isolating a population of cells, a second module configured for activating, genetically modifying, and expanding the population of cells, and a third module configured for harvestingthe expanded population of cells.
In an embodiment, a tubing module for a bioprocessing system includes a first tubing holder block configured to receive at least one pump tube and hold the at least one pump tube in position for selective engagement with a peristaltic pump, a second tubing holder block configured to receive a plurality of pinch valve tubes and hold each pinch valve tube of the plurality of pinch valve tubes in position for selective engagement with a respective actuator of a pinch valve array, and wherein the first tubing holder block and the second tubing holder block are interconnected.
A system for bioprocessing includes a tray having plurality of sidewalls and a bottom surface defining an interior compartment, and a generally open top, and an opening formed in the bottom surface of the tray, the opening having a perimeter. The perimeter of the opening is shaped and/or dimensioned such that a bioreactor vessel can be positioned above the opening and supported by the bottom surface of the tray while a portion of the bioreactor vessel is accessible through the opening in the bottom surface. The tray is receivable within a processing chamber such that the bed plate extends through the opening in the bottom surface of the tray to support the bioreactor vessel.
An apparatus for bioprocessing includes a housing, a drawer receivable within the housing, the drawer including a plurality of sidewalls and a bottom defining a processing chamber, and a generally open top, the drawer being movable between a closed position in which the drawer is received within the housing, and an open position in which the drawer extends from the housing enabling access to the processing chamber through the open top, and at least one bed plate positioned within the processing chamber and configured to receive a bioreactor vessel.
A non-transitory computer readable medium includes instructions configured to adapt a controller to maintain a first target environment in a bioreactor vessel containing a population of cells for a first incubation period to produce a population of genetically modified cells from the population of cells, initiate a flow of media to the bioreactor vessel, maintain a second target environment in the bioreactor vessel for a second incubation period to produce an expanded population of genetically modified cells.
A bioprocessing method for cell therapy includes the steps of genetically modifying a population of cells in a bioreactor vessel to produce a population of genetically modified cells, and expanding the population of genetically modified cells within the bioreactor vessel to generate a number of genetically modified cells sufficient for one or more doses for use in a cell therapy treatment without removing the population of genetically modified cells from the bioreactor vessel.Cells are settled on a gas permeable, liquid impermeable membrane for expansion, and are resuspended when, or after, the desired cell density is reached.
A bioprocessing system includes a first fluid assembly having a first fluid assembly line connected to a first port of a first bioreactor vessel though a first bioreactor line of a first bioreactor vessel, a second fluid assembly having a second fluid assembly line connected to a second port of the first bioreactor vessel through a second bioreactor line of the first bioreactor vessel, and an interconnect line providing for fluid communication between the first fluid assembly and the second fluid assembly, and for fluid communication between the second bioreactor line of the first bioreactor vessel and the first bioreactor line of the first bioreactor vessel.
A bioreactor vessel includes a bottom plate, a vessel body coupled to the bottom plate, the vessel body and the bottom plate defining an interior compartment therebetween, and a plurality of recesses formed in the bottom plate, each recess of the plurality of recesses being configured to receive a corresponding alignment pin on a bed plate for aligning the bioreactor vessel on the bed plate.
Disclosed is a biological sample receiver (100) comprising: a planar substrate (10) for receiving a biological sample including a surface area (11) for accepting a biological sample; an envelope (25) substantially surrounding the substrate, said envelope including an opening (34) for facilitating the deposit of a biological sample onto said surface area (11); and a protective cover (40,50,60) formed around the envelope said protective cover including a closure panel (60) moveable at least to a first position where the opening (34) of the envelope is at least partially concealed, and to a second position where the opening (34) is exposed at least sufficiently to allow said deposit, the protective cover (40,50,60) being arranged further to allow the slidable separation of the envelope from the cover; the device being characterised in that said envelope and said cover are formed from a single sheet (15) of folded material.
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
G01N 1/00 - SamplingPreparing specimens for investigation
79.
METHOD, APPARATUS, SYSTEM AND COMPUTER PROGRAM PRODUCT RELATING TO FILTRATION PROCESS
Methods for selecting a filter for a filtration process are described. Input data is received, and based on the input data, one or more filter characteristics for each of a plurality of filter candidates for a filtration process are identified. Process parameters of the filtration process are identified. A computer-implemented simulation process of the filtration process for each of the plurality of filter candidates is performed, based on the identified process parameters and identified filter characteristics. One or more output characteristics of the filtration process are determined based on the simulation. A filter candidate of the plurality of filter candidates is selected based on the one or more output characteristics.
This present invention provides means for cell harvesting and isolation to be carried out with a single apparatus. This represents a more convenient way for the processing of cells compared with known methods and represents a useful development for the manufacture of cell therapies.
The present invention relates to a flexible bag, a perfusion filter and a fluid port. The fluid port comprises: - a first fluid connection (3; 3'); - a second fluid connection (5; 5') being in fluid communication with the first fluid connection (3; 3'); - an intermediate fluid path (7: 7') connecting the first fluid connection (3; 3') with the second fluid connection (5; 5'); wherein said intermediate fluid path (7; 7') at least a portion of which comprises a substantially right-angled bend (9; 9'); - a protection cap (11; 11') protecting at least the bend (9; 9') of the intermediate fluid part (7; 7') from contact with other objects; and - a connection surface (13; 13') configured for sealing to a film of an object to be supplied by said port, said connection surface will, when sealed to the film of the object, together with the film provide a fluid tight seal surrounding the first fluid connection (3; 3').
The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds.
Provided is a Coriolis flow sensor assembly that includes a fluid flow assembly, including a flow tube, wherein the fluid flow assembly is configured to provide a flow path through the flow tube. The flow tube has at least one region of increased stiffness, which may be a result of a structural support component coupled to the flow tube. In another embodiment, the increased stiffness is caused by integral properties of the flow tube.
Provided is a Coriolis flow sensor assembly that includes a flow tube configured to provide a flow path through the flow tube. Further, the Coriolis flow sensor assembly includes a mechanical drive assembly configured to drive an oscillation of the flow tube while fluid is flowing via an oscillation surface. The Coriolis flow sensor assembly includes an interface fixedly coupled to the oscillation surface of the mechanical drive assembly and configured to receive the flow tube.
Disclosed is a method of bioprocessing includes the steps of combining a suspension comprising a population of cells with magnetic beads to form a population of bead-bound cells in the suspension, isolating the population of bead-bound cells on a magnetic isolation column, and collecting target cells from the population of cells. Collecting the target cells includes dislodging bead-bound cells from the isolation column with an air plug. Also disclosed is a system including magnetic field generator, a magnetic cell isolation holder,a disposable fluidic kit and related methods of their use.
The present invention relates to a method of radiochemical synthesis. Novel methods useful in the synthesis of a positron emission tomography (PET) tracer, and novel intermediates useful in said method are provided that have advantages over known methods.
A medical system useful in the determination of future disease progression in a subject. More specifically the present invention applies machine learning techniques to aid prediction of disease pathology and clinical outcomes in subjects presenting with symptoms of cognitive decline and to expedite clinical development of novel therapeutics.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
88.
MEDICAL SYSTEM FOR DIAGNOSING COGNITIVE DISEASE PATHOLOGY AND/OR OUTCOME
A medical system useful in the determination of future disease progression in a subject. More specifically the present invention applies machine learning techniques to aid prediction of disease pathology and clinical outcomes in subjects presenting with symptoms of cognitive decline and to expedite clinical development of novel therapeutics.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
89.
SYSTEMS FOR UTILIZING CROSSFLOW FILTRATION FOR CELL ENRICHMENT
A disposable cell enrichment kit includes a crossflow filtration device configured to be disposed along a main loop pathway and to receive a process volume containing a biological sample and utilize crossflow filtration, via a micro-porous membrane, to retain a specific cell population in a retentate from the process volume and to remove a permeate including certain biological components from the process volume. The crossflow filtration device includes a laminated filtration unit that includes the micro-porous membrane, a first mating portion, a second mating portion, and a membrane support. The membrane support includes a first plurality of structural features that define a first plurality of openings, wherein the first plurality of structural features are coupled to the micro-porous membrane and provide support to the micro-porous membrane, and the first plurality of openings allow the permeate to flow through them after crossing the micro-porous membrane.
Disclosed is a nucleic acids storage device comprising one or more sealable storage wells, the or each well containing one or more three dimensional solid supports capable of absorbing 5µL or more of liquids containing any nucleic acids to be stored.Disclosed also is a method for storing nucleic acids, the method comprising, in any suitable order, the steps of:providing the device mentioned above; adding liquids, including any nucleic acids to be stored, to the storage well and thereby to be absorbed by the or each solid support in the storage well;allowing said liquids to dry substantially; sealing the or each storage well; and storing the device at room temperature.
The present invention relates to the field of radioactive substances and in particular to a method to facilitate handling of radioactive solutions. Provided by the present invention is a device that enables preparation of capsules filled with radioactivity. More particularly, the radioactivity is suitable for use in certain radiopharmaceutical procedures. The present invention provides improved accuracy and uniformity of patient doses. Furthermore, the potential for spills and needle stick injuries is reduced and the radiation burden is reduced.
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Chemicals for pharmaceutical use, veterinary use; sanitary
products for medical use and for intimate hygiene; dietetic
substances for medical use; material for dental fillings
and dental impressions; disinfectant products for sanitary
and medical use; disinfectants for medical, surgical,
dental and veterinary instruments (other than soap). Chemical research; biochemical research.
95.
DRUG DESIGN FOR APPLICATION-DEPENDENT PAYLOAD, CONTROLLED PHARMACOKINETIC DISTRIBUTION, AND RENAL CLEARANCE
Design and use of an administered drug in the form of a nanoparticle or molecule is described. In certain examples, the nanoparticle has a core and a shell surrounding the core. The core may be configured or designed to provide useful X-ray attenuating properties, gamma ray emission properties, magnetic properties, or therapeutic effects. The nanoparticle or molecule either has a size range minimum larger than about 3-4 nm and a size range maximum smaller than about 5-6 nm so as to remain in the blood pool during imaging or has a size range maximum selected to be smaller than about 3-4 nm so as to distribute from the blood pool during imaging, while still being eliminated by the kidneys.
The present invention relates to calibration and normalization systems and methods for ensuring the quality of radiopharmaceuticals during the synthesis thereof, such as radiopharmaceuticals used in Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT).
B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
The invention discloses a bioreactor 10 for cell culture and expansion, comprising a bioreactor chamber 17, a filter 13 disposed within the chamber 17 and at least one tether 14 loosely tethering the filter to the bioreactor chamber. In an embodiment, the tether(s) allow the filter 13 to move from side to side and/or up and down within the chamber 17, preferably without touching an inner surface of the bioreactor chamber 17. Alternatives show, two, three or four tethers, but one or more tethers can be used.
Disclosed is a hollow fiber filter arrangement (1; 101; 201) and a bioreactor system comprising such a hollow fiber filter arrangement. The hollow fiber filter arrangement comprising: an inlet (3; 103; 203) for receiving a sample to be filtered in the hollow fiber filter arrangement; an outlet (5; 105; 205) for delivering of the filtered sample out from the hollow fiber filter arrangement; a bundle of elongate hollow fibers (7; 107; 207) connected at a first end (9a; 109a; 209a) to the inlet (3; 103; 203) and connected at an opposite second end (9b; 109b; 209b) to the outlet (5; 105; 205); and an outer housing (13; 113; 213) enclosing the bundle (7; 107; 207), wherein a filtrate/waste collection space (15; 115; 215) is provided between the outer housing and the at least one elongated hollow fiber, and wherein the outer housing (13; 113; 213) is made from a flexible material.
Disclosed is a method for the recovery of nucleic acids from a solid support, the method comprising the steps, in any suitable order, of: a) providing a solid support at least a region of which is absorbent and impregnated with a chaotropic agent; b) combining a biological sample, possibly including nucleic acids, with the region; c) washing the region in a washing buffer solution; d) simultaneously heating and agitating the region in a further buffer solution; e) separating the region from the further buffer solution; f) extracting at least a portion of any remaining further buffer solution from the region to provide an extracted buffer solution; g) combining the further buffer solution and the extracted buffer solution portion; and h) subsequently processing the combined buffer solutions in order to amplify any nucleic acids in said combined solution. Hardware suitable for implementing the above method and a kit of parts is disclosed also
The present invention relates to a device and method for sample preparation and collection. More closely the invention relates to a device to isolate DNA, RNA and proteins or other biomolecules in one single step from the same undivided sample
